Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine.

作者信息

Jedrychowski M, Feifel N, Bieck P R, Schmidt E K

机构信息

Human Pharmacology Institute, CIBA-GEIGY GmbH, Tübingen, Germany.

出版信息

J Pharm Biomed Anal. 1993 Mar;11(3):251-5. doi: 10.1016/0731-7085(93)80205-f.

DOI:10.1016/0731-7085(93)80205-f

PMID:8518326

Abstract

摘要

相似文献

Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine.

J Pharm Biomed Anal. 1993 Mar;11(3):251-5. doi: 10.1016/0731-7085(93)80205-f.

Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.

Eur J Clin Pharmacol. 1993;45(3):265-9. doi: 10.1007/BF00315394.

Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection.

J Chromatogr. 1989 Mar 17;488(1):275-82. doi: 10.1016/s0378-4347(00)82952-7.

Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.

Br J Clin Pharmacol. 2000 Feb;49(2):180-4. doi: 10.1046/j.1365-2125.2000.00120.x.

The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.

Eur J Clin Pharmacol. 1989;36(3):319-21. doi: 10.1007/BF00558167.

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.

Clin Pharmacol Ther. 2001 Oct;70(4):327-35.

Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.

Eur J Clin Pharmacol. 1998 Jul;54(5):431-5. doi: 10.1007/s002280050488.

Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).

Eur J Clin Pharmacol. 1999 Jun;55(4):279-83. doi: 10.1007/s002280050629.

The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.

Br J Clin Pharmacol. 1994 Apr;37(4):389-91. doi: 10.1111/j.1365-2125.1994.tb04294.x.

Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.

Clin Pharmacol Ther. 1994 Aug;56(2):176-83. doi: 10.1038/clpt.1994.121.

引用本文的文献

Metabolism of monoamine oxidase inhibitors.

Cell Mol Neurobiol. 1999 Jun;19(3):411-26. doi: 10.1023/a:1006901900106.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验